Acelrx Pharmaceuticals Accounts Payable

Acelrx Pharmaceuticals (ACRX) currently reports a accounts payable of $930K as of March 2026. That compares with $330K in the prior-year period — up 184.4% year over year. Use the charts on this page to explore Acelrx Pharmaceuticals's accounts payable history and peer comparisons.

Acelrx Pharmaceuticals's accounts payable increased from $330K to $930K — a 184.4% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Acelrx Pharmaceuticals reported $930K in accounts payable as of March 2026. That compares with $330K in the prior-year period — up 184.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $930K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Acelrx Pharmaceuticals, and consider following ACRX for alerts when major investors trade the stock.

Acelrx Pharmaceuticals is classified in the Healthcare sector. On accounts payable, it currently shows $930K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ACRX with unrelated industries.